WALTHAM, Mass • 2023-06-20

BostonGene Highlights Approach to IO Research and Precision Medicine at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference

5 min to read

BostonGene announced today that it will participate in and present at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference
WALTHAM, Mass, June 20, 2023

BostonGene announced today that it will participate in and present at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference on June 22 - 23 in Boston, MA. The event brings together academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest advancements in the development of ADCs, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy. BostonGene will also exhibit at the conference.

BostonGene session details can be found below:



Elucidation of the Cellular and Molecular Features of the TME Underlying Immune Escape and IO Failure

  • Friday, June 23 | 9:30 AM ET

  • Speaker: Alexander Bagaev, PhD, Vice President, Product Development, BostonGene


Multiple molecular and cellular factors can influence poor patient responses to immunotherapy and IO clinical trial failure.  Although the involvement of these factors is known to impact patient responses, they are often not considered in IO clinical trial enrollment and therapeutic decision-making.  This session will address how BostonGene bridges this gap by providing a comprehensive profile or portrait of a patient’s disease for therapy selection and stratification for IO clinical trials.

To learn more or to schedule a meeting with BostonGene during the event, please contact Maria Proia at maria.proia@bostongene.com.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com